Abeer Fayyad, MD
Internal Medicine · Flint, MINPI 1093704785
Payments from drug & device makers
Across 261 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$549
- AbbVie$435
- Amgen$385
- AstraZeneca$324
- GSK$299
- Boehringer Ingelheim$293
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,87899%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $549 |
| AbbVie | 39 | $435 |
| Amgen | 21 | $385 |
| AstraZeneca(2 entities) | 22 | $324 |
| GSK | 28 | $299 |
| Boehringer Ingelheim | 15 | $293 |
| Pfizer | 16 | $274 |
| Lilly USA, LLC | 18 | $264 |
| Corcept Therapeutics | 3 | $150 |
| Novartis | 7 | $125 |
| Edwards Lifesciences | 1 | $117 |
| Bayer | 6 | $91 |
| Abbott | 3 | $58 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Indivior Inc. | 2 | $38 |
| Merck | 3 | $38 |
| Fidia Pharma USA Inc. | 2 | $37 |
| Fortovia Therapeutics, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Vivus LLC | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Pulmonx Corporation | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
| Covidien LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$117
- Korlym$104
How this compares
$3,906 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $138,690 |
| JardianceEmpagliflozin | 120 | $136,725 |
| MounjaroTirzepatide | 55 | $102,742 |
| TrulicityDulaglutide | 43 | $93,256 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $79,292 |
| OzempicSemaglutide | 48 | $60,569 |
| ProliaDenosumab | 17 | $29,276 |
| XareltoRivaroxaban | 25 | $28,932 |
| RybelsusSemaglutide | 19 | $27,758 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $24,441 |
| JanuviaSitagliptin Phosphate | 19 | $21,636 |
| EntrestoSacubitril/Valsartan | 21 | $18,299 |
| FarxigaDapagliflozin Propanediol | 11 | $14,230 |
| MyrbetriqMirabegron | 15 | $10,870 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $9,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $264 | $195,99998 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $293 | $149,578143 claims |
| PfizerEliquis, Paxlovid | $274 | $144,238120 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $299 | $107,541139 claims |
| Novo NordiskOzempic, Rybelsus | $549 | $88,32767 claims |
| AmgenProlia | $385 | $29,27617 claims |
| MerckJanuvia | $38 | $21,63619 claims |
| NovartisEntresto | $125 | $18,29921 claims |
| AstraZenecaFarxiga | $324 | $14,23011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Flint
- Ahmed ArifFlint$4.1M
- Wajdi Al ShweiatFlint$841K
- Henry MendozaFlint$175K
- Khalid AhmedFlint$174K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.